QR Kod

RRM2‐targeted nanocarrier enhances radiofrequency ablation efficacy in hepatocellular carcinoma through ferroptosis amplification and immune remodeling

Abstract Hepatocellular carcinoma (HCC) is associated with high mortality rates despite the widespread application of radiofrequency ablation (RFA), which has limited therapeutic efficacy as a monotherapy. This study investigated ribonucleotide reductase M2 (RRM2) upregulation in post‐RFA HCC tissue...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Weiliang Hou, Weifeng Hong, Songhua Cai, Dandan Guo, Zhiping Yan, Jinyu Zhu, Yang Shen, Juncheng Wan, Xudong Qu, Wen Zhang, Runkang Zhao, Zhao Xie, Zhongji Chen, Tong Jiang, Yaling Lin, Wenlong Jia, Ling Wang, Zhao Huang, Xuexin Li, Bufu Tang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wiley 2025-10-01
Seri Bilgileri:iMeta
Konular:
ferroptosis
hepatocellular carcinoma
nanocarrier
radiofrequency ablation
ribonucleotide reductase M2
Online Erişim:https://doi.org/10.1002/imt2.70067
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller